Janet Mj Hammond
CIK: 0001829899
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Atea Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
Exercise(M)Direct58.1K shares- - Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
Tax Payment(F)Direct14.1K shares at avg. $4.24$60K - Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
177K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
Exercise(M)Direct46.8K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
Award(A)Direct11.3K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
Tax Payment(F)Direct14.1K shares at avg. $3.06$43K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Exercise(M) | 58,050 | - | $0 | Direct |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Tax Payment(F) | 14,136 | $4.24 | $59,937 | Direct |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 177,000 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Exercise(M) | 46,800 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Award(A) | 11,250 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Tax Payment(F) | 14,134 | $3.06 | $43,250 | Direct |
1-6 of 6 transactions
About Hammond Janet MJ
Hammond Janet MJ (SEC CIK 0001829899) files insider reports with the SEC as Chief Development Officer of Atea Pharmaceuticals, Inc. (AVIR).
Signal8 holds 2 ownership filings by Hammond Janet MJ, all Form 4s, filed between Feb 4, 2025 and Feb 3, 2026. Those filings report 6 transactions, from Jan 31, 2025 to Jan 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hammond Janet MJ's filings is in BOSTON, MA.
Recent filings by Hammond Janet MJ
- Jan 31, 2026: Option exercise of AVIR shares (Form 4, code M).
- Jan 31, 2026: Tax withholding of AVIR shares (Form 4, code F).
- Jan 31, 2026: Grant or award of AVIR derivative securities (Form 4, code A).
- Jan 31, 2025: Option exercise of AVIR shares (Form 4, code M).
- Jan 31, 2025: Grant or award of AVIR shares (Form 4, code A).
Other insiders filing for Atea Pharmaceuticals, Inc. (AVIR)
- Lucidi Bruno, Director
- BERGER FRANKLIN M, Director
- Berman Howard, Director
- DUNCAN BARBARA GAYLE, Director
- Polsky Bruce, Director
- Murphy Polly A., Director